Treatment-emergent AEs by cohort, grades 3 and 4, in ≥10% of patients
| . | Cohort 1 . | Cohort 2 . | Cohort 3 . | Cohort 3A . | Cohort 4 . | Cohort 5 . | Cohort 5A . | Total . |
|---|---|---|---|---|---|---|---|---|
| . | RO 0.30 mg/kg + Venetoclax 400 mg, n (%) . | RO 0.45 mg/kg + Venetoclax 400 mg, n (%) . | RO 0.45 mg/kg + Venetoclax 600 mg, n (%) . | RO 0.45 mg/kg + Venetoclax 600 mg + Rituximab 375 mg/m2, n (%) . | RO 0.45 mg/kg + Venetoclax 800 mg, n (%) . | RO 0.65 mg/kg + Venetoclax 600 mg, n (%) . | RO 0.65 mg/kg + Venetoclax 600 mg + Rituximab 375 mg/m2, n (%) . | . |
| Patients, n | 3 | 6 | 9 | 7 | 4 | 4 | 6 | 39 |
| Neutropenia | 1 (33.3) | 1 (16.7) | 5 (55.6) | 1 (14.3) | 0 | 2 (50.0) | 1 (16.7) | 11 (28.2) |
| Anemia | 0 | 3 (50.0) | 1 (11.1) | 1 (14.3) | 1 (25.0) | 2 (50.0) | 1 (16.7) | 9 (23.1) |
| Thrombocytopenia | 0 | 2 (33.3) | 2 (22.2) | 2 (28.6) | 0 | 2 (50.0) | 1 (16.7) | 9 (23.1) |
| Hypokalemia | 0 | 0 | 0 | 1 (14.3) | 1 (25.0) | 0 | 3 (50.0) | 5 (12.8) |
| Febrile Neutropenia | 0 | 1 (16.7) | 2 (22.2) | 0 | 0 | 0 | 1 (16.7) | 4 (10.3) |
| . | Cohort 1 . | Cohort 2 . | Cohort 3 . | Cohort 3A . | Cohort 4 . | Cohort 5 . | Cohort 5A . | Total . |
|---|---|---|---|---|---|---|---|---|
| . | RO 0.30 mg/kg + Venetoclax 400 mg, n (%) . | RO 0.45 mg/kg + Venetoclax 400 mg, n (%) . | RO 0.45 mg/kg + Venetoclax 600 mg, n (%) . | RO 0.45 mg/kg + Venetoclax 600 mg + Rituximab 375 mg/m2, n (%) . | RO 0.45 mg/kg + Venetoclax 800 mg, n (%) . | RO 0.65 mg/kg + Venetoclax 600 mg, n (%) . | RO 0.65 mg/kg + Venetoclax 600 mg + Rituximab 375 mg/m2, n (%) . | . |
| Patients, n | 3 | 6 | 9 | 7 | 4 | 4 | 6 | 39 |
| Neutropenia | 1 (33.3) | 1 (16.7) | 5 (55.6) | 1 (14.3) | 0 | 2 (50.0) | 1 (16.7) | 11 (28.2) |
| Anemia | 0 | 3 (50.0) | 1 (11.1) | 1 (14.3) | 1 (25.0) | 2 (50.0) | 1 (16.7) | 9 (23.1) |
| Thrombocytopenia | 0 | 2 (33.3) | 2 (22.2) | 2 (28.6) | 0 | 2 (50.0) | 1 (16.7) | 9 (23.1) |
| Hypokalemia | 0 | 0 | 0 | 1 (14.3) | 1 (25.0) | 0 | 3 (50.0) | 5 (12.8) |
| Febrile Neutropenia | 0 | 1 (16.7) | 2 (22.2) | 0 | 0 | 0 | 1 (16.7) | 4 (10.3) |